Jacobio Pharmaceuticals Group Co., Ltd. (01167.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

6.0x

Market Cap

HKD 4.99B

MomentumView details →

1D Return

+1.90%

YTD Return

+1.10%

RSI (14)

65.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

6.0x

Market Cap

HKD 4.99B

RSI (14)

65.7

MomentumView details →

1D Return

+1.90%

YTD Return

+1.10%

ProfitabilityView details →

Gross Margin

95.61%

Net Margin

49.59%

EBITDA Margin

49.19%

ROE (TTM)

34.13%

ROA (TTM)

24.75%

Asset Turnover

0.59x

GrowthView details →

Revenue YoY

+789.17%

EPS YoY

+158.52%

FCF YoY

+76.06%

Revenue CAGR 3Y

−18.34%

EPS CAGR 3Y

+10.00%

EBITDA YoY

+152.59%

EarningsView details →

EPS (Actual)

HKD 0.89

EPS Surprise

7612.31%

Beats (12Q)

1/12

Next Q EPS Est

—

Avg Surprise (4Q)

7612.31%

Rev Surprise

11.79%

Capital & dividendView details →

Debt/Equity

0.12x

Current Ratio

8.28x

Quick Ratio

8.28x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

929.89M

Net Income (TTM)

461.15M

Op. CF (TTM)

—

Next earningsMar 24, 2027 →

Latest newsMore news →

Jacobio Pharma completed the first patient dosing in the Phase IIa clinical trial of its BET inhibitor JAB-8263 for rheumatoid arthritis in China.40d ago

Similar companies

三力制药603439.SH ACADIA Pharmaceuticals Inc.ACAD 康辰药业603590.SH 科兴制药688136.SH 博拓生物688767.SH Apellis Pharmaceuticals, Inc.APLS Find similar companies →

Latest newsMore news →

Jacobio Pharma completed the first patient dosing in the Phase IIa clinical trial of its BET inhibitor JAB-8263 for rheumatoid arthritis in China.40d ago